FRX vs. DNA, TLRY, VBV, CUS, AIM, IPA, APM, GXE, ITH, and CRDL
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Dalradian Resources (DNA), Tilray Brands (TLRY), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), International Tower Hill Mines (ITH), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs.
Dalradian Resources (TSE:DNA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Dalradian Resources received 101 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. However, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 66.78% of users gave Dalradian Resources an outperform vote.
Dalradian Resources has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Dalradian Resources' return on equity.
52.8% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Given Dalradian Resources' higher possible upside, equities analysts clearly believe Dalradian Resources is more favorable than Fennec Pharmaceuticals.
In the previous week, Dalradian Resources' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.
Dalradian Resources has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Dalradian Resources, indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats Dalradian Resources on 8 of the 13 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy FRX Stock Free FRX Stock Alerts